key: cord-0912978-x80ajwgv authors: Harano, Takashi; Ryan, John P.; Chan, Ernest G.; Noda, Kentaro; Morrell, Matthew R.; Luketich, James D.; Sanchez, Pablo G. title: Lung transplantation for the treatment of irreversible acute respiratory distress syndrome date: 2020-12-15 journal: Clin Transplant DOI: 10.1111/ctr.14182 sha: 0f0de32ef7a48d8dd6711f3267827c526464b6d2 doc_id: 912978 cord_uid: x80ajwgv BACKGROUND: Despite advances in critical care for acute respiratory distress syndrome (ARDS), some survivors in the acute phase are unable to wean from extracorporeal membrane oxygenation (ECMO) or mechanical ventilation. To date, little is known regarding whether lung transplantation confers a survival benefit for irreversible ARDS. METHODS: This retrospective study was conducted using the United Network for Organ Sharing database (May 2005–December 2018). Patients with restrictive lung disease were divided into two groups: patients with and without ARDS. Propensity score matching identified recipients without ARDS for the control group. RESULTS: A total of 63 patients with ARDS were waitlisted for lung transplantation, while 39 received a lung transplant after a median waitlist duration of 8 days. Seventy‐eight patients were matched as controls. In the ARDS group, the median age was 30 years, and the median lung allocation score was 88.4. Among the 39 recipients, 30 (76.9%) received ECMO support prior to transplantation. Lung transplantation for ARDS and restrictive lung disease showed similar 90‐day (87.2% vs. 88.5%, p = .80), 1‐year (82.1% vs. 85.9%, p = .52), and 3‐year (69.2% vs. 65.4%, p = .94) survival rates. CONCLUSIONS: Lung transplantation provides acceptable outcomes in selected patients with irreversible ARDS. As other treatment modalities, such as ECMO or prolonged mechanical ventilatory support, have been successful in the setting of ARDS, the use of lung transplantation remains relatively low. However, there remains a substantial number of patients who may benefit from a lung transplant, such as those with persistent ARDS who are unable to recover while on ECMO or mechanical ventilatory support due to devastating lung injuries, as well as patients with chronic pulmonary symptoms after recovery when bronchiectasis and pulmonary fibrosis persist on chest CT. 6 To date, the literature consists of 10 case reports [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and 1 single-center case series 20 ( Figure 2) . Table 5 This is particularly intriguing as the outcomes of ECMO as a bridge to lung transplantation, which is one of the biggest risk factors for early mortality, were reported to be 57%-93% at 12 months [23] [24] [25] [26] [27] [28] and 62%-80% at 3 years. 25 In conclusion, the current study demonstrates that the use of lung transplantation in the setting of end-stage lung disease secondary to ARDS can provide a reasonable survival benefit when compared to alternative therapies. Trends show that national practices favor the use of lung transplantation in younger recipients who are in critical condition requiring ECMO and/or mechanical ventilation support. A more detailed review is required regarding best practices in order to maximize long-term survival and allograft function. The data reported here have been supplied by UNOS as the contractor for the OPTN. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or an interpretation by the OPTN or the US Government. The authors would like to thank Editage (http://www.edita ge.com) for language editing and proofreading. TH participated in the research design, writing of the paper, performance of the research, and data analysis; JPR participated in the writing of the paper, performance of the research, and data analysis; The data that support the findings of this study are available from Organ Procurement and Transplantation Network (OPTN) data. Data are available from the authors with the permission of the Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome Lung protective ventilation strategy for the acute respiratory distress syndrome Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome Past and present ARDS mortality rates: a systematic review Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome The longterm impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status CT predictors of mortality in pathology confirmed ARDS Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases Ambulatory ECMO as a bridge to lung transplant in a previously well pediatric patient with ARDS Double lung transplantation for adult respiratory distress syndrome after recombinant interleukin 2 Lung transplantation in pulmonary fibrosis secondary to influenza A pneumonia Single lung transplantation for adult respiratory distress syndrome after paraquat poisoning Lung transplantation following 107 days of extracorporeal membrane oxygenation Lung transplantation after 125 days on ECMO for severe refractory hypoxemia with no prior lung disease Emergency lung transplantation after extracorporeal membrane oxygenation Lung transplantation for elderly patients with end-stage COVID-19 pneumonia Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCRpositive patient Lung transplantation as a therapeutic option in acute respiratory distress syndrome Is there an age limit to lung transplantation? OPTN/SRTR 2017 annual data report: lung Awake extracorporeal membrane oxygenation as bridge to lung transplantation: a 9-year experience Efficacy of extracorporeal membrane oxygenation as a bridge to lung transplantation Extracorporeal membrane oxygenation as a bridge to lung transplant: midterm outcomes Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation Outcomes and temporal trends among high-risk patients after lung transplantation in the United States Growing experience with extracorporeal membrane oxygenation as a bridge to lung transplantation Lung transplantation for the treatment of irreversible acute respiratory distress syndrome